CN1204405C - 组织微阵列生物芯片 - Google Patents
组织微阵列生物芯片 Download PDFInfo
- Publication number
- CN1204405C CN1204405C CN 01128783 CN01128783A CN1204405C CN 1204405 C CN1204405 C CN 1204405C CN 01128783 CN01128783 CN 01128783 CN 01128783 A CN01128783 A CN 01128783A CN 1204405 C CN1204405 C CN 1204405C
- Authority
- CN
- China
- Prior art keywords
- tissue
- samples
- different
- same
- array
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000002493 microarray Methods 0.000 title claims abstract description 396
- 238000000018 DNA microarray Methods 0.000 title claims description 240
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 330
- 201000010099 disease Diseases 0.000 claims abstract description 327
- 238000002360 preparation method Methods 0.000 claims abstract description 51
- 239000012188 paraffin wax Substances 0.000 claims abstract description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 120
- 210000004027 cell Anatomy 0.000 claims description 81
- 238000011282 treatment Methods 0.000 claims description 69
- 210000000056 organ Anatomy 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 44
- 230000004069 differentiation Effects 0.000 claims description 34
- 241001465754 Metazoa Species 0.000 claims description 32
- 230000008520 organization Effects 0.000 claims description 29
- 230000000306 recurrent effect Effects 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 27
- 238000004043 dyeing Methods 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 238000003745 diagnosis Methods 0.000 claims description 22
- 239000004575 stone Substances 0.000 claims description 19
- 239000001993 wax Substances 0.000 claims description 19
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 16
- 239000011159 matrix material Substances 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 15
- 238000003491 array Methods 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 13
- 230000003902 lesion Effects 0.000 claims description 12
- 230000018044 dehydration Effects 0.000 claims description 11
- 238000006297 dehydration reaction Methods 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 10
- 244000005700 microbiome Species 0.000 claims description 10
- 230000000813 microbial effect Effects 0.000 claims description 8
- 230000009261 transgenic effect Effects 0.000 claims description 8
- 230000001613 neoplastic effect Effects 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 6
- 238000001574 biopsy Methods 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- 206010003445 Ascites Diseases 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 206010048612 Hydrothorax Diseases 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 210000000416 exudates and transudate Anatomy 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 241000235342 Saccharomycetes Species 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims description 2
- 230000003394 haemopoietic effect Effects 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims 3
- 239000002994 raw material Substances 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 238000009941 weaving Methods 0.000 claims 2
- 210000004754 hybrid cell Anatomy 0.000 claims 1
- 238000004458 analytical method Methods 0.000 abstract description 29
- 102000004169 proteins and genes Human genes 0.000 abstract description 11
- 102000039446 nucleic acids Human genes 0.000 abstract description 3
- 108020004707 nucleic acids Proteins 0.000 abstract description 3
- 150000007523 nucleic acids Chemical class 0.000 abstract description 3
- 108091005461 Nucleic proteins Proteins 0.000 abstract 1
- 230000004907 flux Effects 0.000 abstract 1
- 239000011521 glass Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 856
- 239000000523 sample Substances 0.000 description 250
- 108090000623 proteins and genes Proteins 0.000 description 62
- 210000004185 liver Anatomy 0.000 description 52
- 210000003205 muscle Anatomy 0.000 description 46
- 210000001550 testis Anatomy 0.000 description 46
- 210000000496 pancreas Anatomy 0.000 description 45
- 210000002216 heart Anatomy 0.000 description 44
- 210000002307 prostate Anatomy 0.000 description 44
- 210000000952 spleen Anatomy 0.000 description 44
- 210000001685 thyroid gland Anatomy 0.000 description 43
- 210000004100 adrenal gland Anatomy 0.000 description 42
- 210000004556 brain Anatomy 0.000 description 42
- 210000001165 lymph node Anatomy 0.000 description 41
- 206010006187 Breast cancer Diseases 0.000 description 36
- 208000026310 Breast neoplasm Diseases 0.000 description 36
- 238000011160 research Methods 0.000 description 29
- 238000011161 development Methods 0.000 description 28
- 230000018109 developmental process Effects 0.000 description 28
- 238000005516 engineering process Methods 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 23
- 230000003321 amplification Effects 0.000 description 22
- 238000003199 nucleic acid amplification method Methods 0.000 description 22
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 21
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 19
- 210000004072 lung Anatomy 0.000 description 19
- 201000005202 lung cancer Diseases 0.000 description 19
- 208000020816 lung neoplasm Diseases 0.000 description 19
- 206010060862 Prostate cancer Diseases 0.000 description 18
- 201000007270 liver cancer Diseases 0.000 description 18
- 208000014018 liver neoplasm Diseases 0.000 description 18
- 239000000427 antigen Substances 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 210000001161 mammalian embryo Anatomy 0.000 description 15
- 230000007170 pathology Effects 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 101150029129 AR gene Proteins 0.000 description 12
- 206010009944 Colon cancer Diseases 0.000 description 12
- 208000005718 Stomach Neoplasms Diseases 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 208000029742 colonic neoplasm Diseases 0.000 description 12
- 238000002372 labelling Methods 0.000 description 12
- 238000004393 prognosis Methods 0.000 description 12
- 210000000981 epithelium Anatomy 0.000 description 11
- 201000000498 stomach carcinoma Diseases 0.000 description 11
- 210000005048 vimentin Anatomy 0.000 description 11
- 101150029707 ERBB2 gene Proteins 0.000 description 10
- 102000013127 Vimentin Human genes 0.000 description 10
- 108010065472 Vimentin Proteins 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 238000004080 punching Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000001605 fetal effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 108700024542 myc Genes Proteins 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 6
- 102000006311 Cyclin D1 Human genes 0.000 description 6
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 238000007901 in situ hybridization Methods 0.000 description 6
- 244000000010 microbial pathogen Species 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 5
- 108010058546 Cyclin D1 Proteins 0.000 description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 5
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 5
- 101150039798 MYC gene Proteins 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 240000002825 Solanum vestissimum Species 0.000 description 5
- 235000018259 Solanum vestissimum Nutrition 0.000 description 5
- 108700042656 bcl-1 Genes Proteins 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000011532 immunohistochemical staining Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000012775 microarray technology Methods 0.000 description 5
- 239000003147 molecular marker Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 5
- 201000002510 thyroid cancer Diseases 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000043276 Oncogene Human genes 0.000 description 4
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 238000001794 hormone therapy Methods 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- 208000011645 metastatic carcinoma Diseases 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 201000001275 rectum cancer Diseases 0.000 description 4
- 210000005084 renal tissue Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000009871 tenuigenin Substances 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 101100239628 Danio rerio myca gene Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 3
- 239000002313 adhesive film Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 208000019065 cervical carcinoma Diseases 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 229940022353 herceptin Drugs 0.000 description 3
- 238000012309 immunohistochemistry technique Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 108091008800 n-Myc Proteins 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001478240 Coccus Species 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 201000001531 bladder carcinoma Diseases 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000000998 lymphohematopoietic effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000004412 neuroendocrine cell Anatomy 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000010827 pathological analysis Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 201000010174 renal carcinoma Diseases 0.000 description 2
- 210000003660 reticulum Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 101500014499 Arabidopsis thaliana C-terminally encoded peptide 11 Proteins 0.000 description 1
- 101150010856 CRT gene Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000709715 Hepatovirus Species 0.000 description 1
- 206010050808 Hyperchromasia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150117945 PDGFB gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102100039832 Ribonuclease pancreatic Human genes 0.000 description 1
- 101710123428 Ribonuclease pancreatic Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 206010073120 Testicular malignant teratoma Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- OGJLPLDTKZHLLH-UHFFFAOYSA-N [Ca].[Co] Chemical compound [Ca].[Co] OGJLPLDTKZHLLH-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- UYJXRRSPUVSSMN-UHFFFAOYSA-P ammonium sulfide Chemical compound [NH4+].[NH4+].[S-2] UYJXRRSPUVSSMN-UHFFFAOYSA-P 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 208000024753 bloody sputum Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 239000012189 cellwax Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 210000003737 chromaffin cell Anatomy 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000024558 digestive system cancer Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000001861 endoscopic biopsy Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- GGCJLWBMJYGIRE-UHFFFAOYSA-N ethanol;formaldehyde Chemical compound O=C.CCO GGCJLWBMJYGIRE-UHFFFAOYSA-N 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000000231 kidney cortex Anatomy 0.000 description 1
- 210000002415 kinetochore Anatomy 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 108700021652 sis Genes Proteins 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004336 spermatogonium Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 208000004238 testicular teratoma Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 01128783 CN1204405C (zh) | 2001-09-13 | 2001-09-13 | 组织微阵列生物芯片 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 01128783 CN1204405C (zh) | 2001-09-13 | 2001-09-13 | 组织微阵列生物芯片 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1356553A CN1356553A (zh) | 2002-07-03 |
CN1204405C true CN1204405C (zh) | 2005-06-01 |
Family
ID=4668612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 01128783 Ceased CN1204405C (zh) | 2001-09-13 | 2001-09-13 | 组织微阵列生物芯片 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1204405C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101231282B (zh) * | 2007-01-23 | 2011-09-21 | 北京市农林科学院 | 一种用于功能基因组研究的组织芯片、及其制备方法和应用 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100451649C (zh) * | 2004-01-08 | 2009-01-14 | 中南大学湘雅医学院肿瘤研究所 | 一种细胞芯片制作方法及其器具 |
CN1300339C (zh) * | 2004-11-08 | 2007-02-14 | 西安交通大学 | 填埋有组织阵列的蜡块的制备方法 |
CN100360925C (zh) * | 2005-05-12 | 2008-01-09 | 杭州市中医院 | 一一对照式玻片检测方法 |
CN101042316B (zh) * | 2007-04-30 | 2011-01-26 | 孙爱静 | 肿瘤转移拟态组织芯片 |
WO2012078138A1 (en) * | 2010-12-07 | 2012-06-14 | Wei-Sing Chu | Cell array quality control device for pathological analysis |
CN103866402A (zh) * | 2012-12-12 | 2014-06-18 | 泰州医药城博奥邦科生物科技有限公司 | 精子芯片 |
CN103869057B (zh) * | 2012-12-13 | 2017-01-18 | 泰州医药城博奥邦科生物科技有限公司 | 穿刺活检组织芯片 |
CN103900864A (zh) * | 2012-12-25 | 2014-07-02 | 泰州医药城博奥邦科生物科技有限公司 | 脱落细胞芯片 |
CN106769174B (zh) * | 2016-11-22 | 2018-07-13 | 南京林业大学 | 植物组织切片受体空白蜡块钻孔仪 |
CN108088729A (zh) * | 2018-01-18 | 2018-05-29 | 熊中堂 | 组织芯片制作装置及方法 |
CN114383921B (zh) * | 2020-10-19 | 2023-11-21 | 北京龙迈达斯科技开发有限公司 | 一种组织芯片及其制备方法 |
CN113588375B (zh) * | 2021-08-20 | 2023-09-29 | 中科光华(西安)智能生物科技有限公司 | 一种高稳定性骨及骨肿瘤组织微阵列芯片及其制备方法 |
CN114018680B (zh) * | 2021-10-28 | 2022-10-21 | 上海交通大学医学院附属第九人民医院 | 一种脉络膜黑色素瘤标本蜡块及芯片的制作方法 |
-
2001
- 2001-09-13 CN CN 01128783 patent/CN1204405C/zh not_active Ceased
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101231282B (zh) * | 2007-01-23 | 2011-09-21 | 北京市农林科学院 | 一种用于功能基因组研究的组织芯片、及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1356553A (zh) | 2002-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1204405C (zh) | 组织微阵列生物芯片 | |
DK2279266T3 (en) | PROCEDURE FOR DETECTING IGF1R DIFFERENCES IN CIRCULATING TUMOR CELLS USING FISH | |
Neumann et al. | Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch® system and the CellCelector™ | |
CN1308726A (zh) | 用于包括胎儿细胞的计算机所控制的稀少细胞的基于诊断的方法和装置 | |
Petersen et al. | Fluorescence in situ hybridization on formalin-fixed and paraffin-embedded tissue: optimizing the method | |
CN110055325A (zh) | 用于前列腺癌的诊断、预后和评估治疗性/预防性治疗的材料和方法 | |
CN108179134B (zh) | 基于EpCAM/PSMA双抗体功能化微流控芯片及其制备方法和应用 | |
US20230130223A1 (en) | Methods for prostate cancer detection | |
US20180291466A1 (en) | Materials and methods for assessing progression of prostate cancer | |
Singh-Bains et al. | Preparation, construction and high-throughput automated analysis of human brain tissue microarrays for neurodegenerative disease drug development | |
Lyons-Weiler et al. | Optimization of the Affymetrix GeneChip Mapping 10K 2.0 Assay for routine clinical use on formalin-fixed paraffin-embedded tissues | |
CN101037709A (zh) | 玉米真实性检测试剂盒及其检测方法 | |
Zhang et al. | Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas | |
CN113156120B (zh) | B7h4在制备子宫内膜癌分子分型试剂及系统中的应用 | |
CN1766634A (zh) | 一种检测乳腺球蛋白的方法及其试剂盒 | |
Huber et al. | Rapid micro fluorescence in situ hybridization in tissue sections | |
CN110923323B (zh) | 一种Twist基因表达检测试剂盒 | |
CN113348356A (zh) | 用于针对形态学特征和生物标志物表达而制备和分析细胞样品的方法和系统 | |
CN114517233B (zh) | 一种用于结直肠癌早期预警和临床诊断的引物探针组合 | |
Bibbo et al. | How technology is reshaping the practice of nongynecologic cytology | |
CN113917160A (zh) | 采用her2抗体免疫荧光法检测乳腺癌循环肿瘤细胞的特异性方法 | |
Yang et al. | Implementing microwell slides for detection and isolation of single circulating tumor cells from complex cell suspensions | |
US20150247204A1 (en) | Differential diagnosis of hepatic neoplasms | |
CN1557966A (zh) | 适合转基因棉花等外源基因检测的内标准基因及其应用 | |
Reichard et al. | Detection of genetic translocations in lymphoma using fluorescence in situ hybridization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANXI CHAOYING BIOLOGY SCIENCE CO., LTD. Free format text: FORMER OWNER: CHAOYING BIO-MEDICAL RESEARCH AND DEVELOPMENT CO LTD, SHAANXI Effective date: 20051202 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20051202 Address after: 710061 No. 29 South Changan Road, Shaanxi, Xi'an Patentee after: Shaanxi Chaoying Biotechnology Co.,Ltd. Address before: 710032 No. 29 South Changan Road, Shaanxi, Xi'an Patentee before: Shaanxi Chaoying Biomedical Research and Development Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20050601 |
|
CX01 | Expiry of patent term | ||
IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20220429 Decision number of declaring invalidation: 55580 Granted publication date: 20050601 |
|
IW01 | Full invalidation of patent right |